Media stories about Curis (NASDAQ:CRIS) have trended somewhat positive recently, Accern Sentiment reports. Accern scores the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Curis earned a news impact score of 0.07 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 46.2310989379204 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the news headlines that may have impacted Accern Sentiment’s scoring:
Shares of Curis (CRIS) opened at 1.56 on Friday. The firm’s market capitalization is $224.45 million. The company’s 50-day moving average is $1.70 and its 200 day moving average is $1.90. Curis has a 52-week low of $1.47 and a 52-week high of $3.72.
Curis (NASDAQ:CRIS) last released its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.01). The firm had revenue of $2.10 million for the quarter, compared to the consensus estimate of $2.08 million. Curis had a negative net margin of 836.18% and a negative return on equity of 236.43%. The business’s revenue for the quarter was up 23.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.09) earnings per share. Equities analysts expect that Curis will post ($0.39) earnings per share for the current fiscal year.
Several equities analysts have recently weighed in on the stock. Zacks Investment Research downgraded shares of Curis from a “hold” rating to a “sell” rating in a research note on Tuesday, October 3rd. ValuEngine downgraded shares of Curis from a “hold” rating to a “sell” rating in a research note on Friday, September 15th. BidaskClub upgraded shares of Curis from a “strong sell” rating to a “sell” rating in a research report on Thursday, August 17th. Finally, Guggenheim assumed coverage on shares of Curis in a research report on Monday, October 23rd. They set a “buy” rating and a $7.00 price objective for the company. Two analysts have rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company’s stock. Curis presently has a consensus rating of “Hold” and a consensus price target of $6.50.
COPYRIGHT VIOLATION NOTICE: This story was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright & trademark law. The original version of this story can be viewed at https://www.dispatchtribunal.com/2017/10/28/curis-cris-getting-somewhat-favorable-news-coverage-study-finds.html.
Curis Company Profile
Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.
Receive News & Ratings for Curis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.